Dr. McBride, Ms Jiang, and Drs. Abbas, Morimoto, Li, Maciuca, Townsend, and Kennedy may own stock or stock options in F. Hoffmann-La Roche Ltd., the parent company of Genentech, Inc., as part of their general employment compensation.
Systemic Lupus Erythematosus
Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: Results of a phase I, placebo-controlled, double-blind, dose-escalation study†
Article first published online: 27 OCT 2012
Copyright © 2012 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 64, Issue 11, pages 3666–3676, November 2012
How to Cite
McBride, J. M., Jiang, J., Abbas, A. R., Morimoto, A., Li, J., Maciuca, R., Townsend, M., Wallace, D. J., Kennedy, W. P. and Drappa, J. (2012), Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: Results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis & Rheumatism, 64: 3666–3676. doi: 10.1002/art.34632
ClinicalTrials.gov identifier: NCT00541749.
- Issue published online: 27 OCT 2012
- Article first published online: 27 OCT 2012
- Accepted manuscript online: 25 JUL 2012 09:55AM EST
- Manuscript Accepted: 10 JUL 2012
- Manuscript Received: 17 MAR 2011
Additional Supporting Information may be found in the online version of this article.
|ART_34632_sm_SupplTable1.doc||50K||Supplementary Table 1|
|ART_34632_sm_SupplFig1.tif||1386K||Supplementary Figure 1|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.